jRCT2080222501已完成1 期
A PHASE I, OPEN-LABEL, NON-RANDOMIZED, DOSE-ESCALATING, SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC AND EFFICACY STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS,
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 142
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- This is an open-label, non-randomized, dose-escalation, phase 1 study.
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Provided written informed consent for treatment.
- •20 years of age or older at enrollment.
- •Histologically or cytologically confirmed advanced or metastatic solid tumor(s) without standard treatment remains.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 on time of patient's allocation.
排除标准
- •A serious illness or medical conditions.
- •Known hypersensitivity to any drugs similar to TAS-120 in structure or class.
- •Pregnant or lactating female or women of child-bearing potential who have a positive pregnancy test (urine or serum) within 7 days prior to starting the study drug.
结局指标
主要结局
-
safety Safety CTCAE (ver.4.03)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapyadvanced gastric cancerJPRN-UMIN000007421ational Cancer Center Hospital East28
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with genetic abnormalitiesAdvanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-004810-16-DETaiho Oncology Inc385
已完成
2 期
PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONSNL-OMON48846Taiho Oncology, Inc.20
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with genetic abnormalitiesAdvanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-004810-16-PTTaiho Oncology Inc385
已完成
1 期
Phase I/II study of TAS-120JPRN-jRCT2080224117Taiho Pharmaceutical Co., Ltd.20